Jan 20, 2026 9:15 am EST Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
Dec 16, 2025 4:05 pm EST Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
Dec 05, 2025 6:15 am EST Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Dec 03, 2025 7:20 am EST Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
Nov 24, 2025 9:00 am EST Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
Nov 10, 2025 4:01 pm EST Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 03, 2025 9:15 am EST Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
Oct 31, 2025 9:15 am EDT Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
Sep 25, 2025 7:15 am EDT Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting